Panaji
Mumbai-based pharma company, Indoco Remedies posted a healthy Q2 with net revenue standing at Rs 247.70 cr vs Rs 226.40 cr during the same time in the previous fiscal. Net profit was up 0.08 per cent at Rs 22.4 cr vs Rs 22.6 cr in July-Sept quarter of FY14-15.
The company also launched six new products in its Q2 including analgesics in the gynaec and the anti-diabetic segment. For the US markets, Indoco currently holds under it, 61 ANDAs (Abbreviated New Drug Applications).
The pharma player, consisting of 8 manufacturing units posted an EBIDTA of 45.7 vs 48.6 last year during the same period, up 21.5 per cent.
